A federal agency has disclosed a record $31 million payment by pharmaceutical giant GlaxoSmithKline for irregular pricing in Canada. The voluntary compliance agreement is detailed in the latest annual report of the Patented Medicine Prices Review Board: ‘It’s a record, one-time excess revenue repayment.’
This content is for Blacklock’s Reporter members only. Please login to view this content. (Register here.)
